{
    "id": 2,
    "premise": "none",
    "hypothesis": "Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA.",
    "label": "entailment",
    "explanation": "Synthetic lethality is when co-occurrence of multiple genetic events results in cell death.\nPARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA.",
    "results": {
        "semantic validity": false,
        "premise": null,
        "hypothesis": "Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA.",
        "history explanation": [
            "0 iteration: Synthetic lethality is when co-occurrence of multiple genetic events results in cell death.\nPARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA.",
            "1 iteration: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways.\nPARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nIn the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised.",
            "2 iteration: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways.\nPARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nIn the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised.",
            "3 iteration: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways.\nPARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nIn the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised.",
            "4 iteration: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways.\nPARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nIn the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised.",
            "5 iteration: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways.\nPARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nIn the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms.",
            "6 iteration: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways.\nPARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nIn the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms.",
            "7 iteration: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways.\nPARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nIn the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms.",
            "8 iteration: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways.\nPARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nIn the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms.",
            "9 iteration: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways.\nPARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nIn the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms.",
            "10 iteration: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways.\nPARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA.\nIn the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: False",
            "8 iteration: False",
            "9 iteration: False",
            "10 iteration: False"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a relation between SyntheticLethality and CoOccurrence of genetic events resulting in CellDeath. *)\\n(* We can use this to infer that SyntheticLethality implies a reliance on a singular mechanism due to cell death. *)\\nfrom explanation_1 have \"SyntheticLethality w \u27f6 (Agent e y \u2227 Patient e z)\" sledgehammer', 'solving time': 104.27834701538086, 'proof tactics': [], 'code': 'theory clinical_2_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  CoOccurrence :: \"entity \u21d2 bool\"\\n  GeneticEvent :: \"entity \u21d2 bool\"\\n  CellDeath :: \"entity \u21d2 bool\"\\n  ResultIn :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  ReplicationAssociatedDoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  RelyOn :: \"event \u21d2 bool\"\\n  DefectiveHomologousRecombinationRepair :: \"entity \u21d2 bool\"\\n  ErrorProneNonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  RepairDNA :: \"entity \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  RelyOnSingularMechanism :: \"entity \u21d2 bool\"\\n  CumulativeDamageToDNA :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Synthetic lethality is when co-occurrence of multiple genetic events results in cell death. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. SyntheticLethality x \u2227 CoOccurrence y \u2227 GeneticEvent y \u2227 ResultIn e \u2227 CellDeath z \u27f6 (Agent e y \u2227 Patient e z)\"\\n\\n(* Explanation 2: PARP inhibitors cause replication\u2010associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z u v w e. PARPInhibitors x \u2227 Cause y \u2227 ReplicationAssociatedDoubleStrandBreaks z \u2227 Prevent e \u2227 SingleStrandBreakRepair v \u2227 RelyOn w \u2227 DefectiveHomologousRecombinationRepair v \u2227 ErrorProneNonHomologousEndJoining v \u2227 RepairDNA v \u27f6 (Agent e x \u2227 Patient e z \u2227 Agent w x \u2227 Patient w v)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 LossOfBRCA2 y \u2227 PARPInhibitors z \u2227 SyntheticLethality w\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z e. Patients x \u2227 LossOfBRCA2 y \u2227 PARPInhibitors z \u2227 Inhibition z \u2227 Benefit e \u2227 Agent e x \u2227 Patient e z \u2227 SyntheticLethality w \u2227 RelyOnSingularMechanism w \u2227 CumulativeDamageToDNA w\"\\nproof -\\n  (* From the premise, we have known information about Patients, LossOfBRCA2, PARPInhibitors, and SyntheticLethality. *)\\n  from asm have \"Patients x \u2227 LossOfBRCA2 y \u2227 PARPInhibitors z \u2227 SyntheticLethality w\" <ATP>\\n  \\n  (* Explanation 1 provides a relation between SyntheticLethality and CoOccurrence of genetic events resulting in CellDeath. *)\\n  (* We can use this to infer that SyntheticLethality implies a reliance on a singular mechanism due to cell death. *)\\n  from explanation_1 have \"SyntheticLethality w \u27f6 (Agent e y \u2227 Patient e z)\" <ATP>\\n  \\n  (* Explanation 2 provides a relation between PARPInhibitors and the prevention of single strand break repair, *)\\n  (* which relies on defective homologous recombination repair and error-prone non-homologous end joining. *)\\n  from explanation_2 have \"PARPInhibitors z \u27f6 (Agent e z \u2227 Patient e v \u2227 Agent w z \u2227 Patient w v)\" <ATP>\\n  \\n  (* Using the logical relations, we know that PARP inhibitors cause replication-associated double strand breaks, *)\\n  (* which implies reliance on defective homologous recombination repair and error-prone non-homologous end joining. *)\\n  from `PARPInhibitors z` have \"RelyOnSingularMechanism w\" <ATP>\\n  \\n  (* Combining these, we can infer that patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality. *)\\n  have \"Inhibition z \u2227 Benefit e \u2227 CumulativeDamageToDNA w\" <ATP>\\n  \\n  (* Therefore, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: cell death (from Explanatory Sentence 1)\\nC: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nD: prevention of single strand break repair (from Explanatory Sentence 2)\\nE: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nF: reliance on error-prone non-homologous end joining to repair DNA (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nEquivalent(A, B)\\nEquivalent(co-occurrence of multiple genetic events, cell death)\\n--------\\nImplies(C, D)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, prevention of single strand break repair)\\n--------\\nImplies(D, And(E, F))\\nImplies(prevention of single strand break repair, E & F)\\n--------\\n\\nDerived Implications:\\nImplies(B, A)\\nImplies(cell death, co-occurrence of multiple genetic events)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(reliance on defective homologous recombination repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(Not(A), Not(B))\\nImplies(Not(co-occurrence of multiple genetic events), Not(cell death))\\n--------\\nImplies(Not(F), Not(D))\\nImplies(Not(reliance on error-prone non-homologous end joining to repair DNA), Not(prevention of single strand break repair))\\n--------\\nImplies(Not(E), Not(D))\\nImplies(Not(reliance on defective homologous recombination repair), Not(prevention of single strand break repair))\\n--------\\nImplies(D, F)\\nImplies(prevention of single strand break repair, reliance on error-prone non-homologous end joining to repair DNA)\\n--------\\nImplies(D, E)\\nImplies(prevention of single strand break repair, reliance on defective homologous recombination repair)\\n--------\\nImplies(C, F)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on error-prone non-homologous end joining to repair DNA)\\n--------\\nImplies(C, E)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on defective homologous recombination repair)\\n--------\\nImplies(Not(B), Not(A))\\nImplies(Not(cell death), Not(co-occurrence of multiple genetic events))\\n--------\\nImplies(Not(F), Not(C))\\nImplies(Not(reliance on error-prone non-homologous end joining to repair DNA), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(A, B)\\nImplies(co-occurrence of multiple genetic events, cell death)\\n--------\\n'}",
            "1 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 7.481822967529297, 'proof tactics': ['Type unification failed: Clash of types \"event\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Mechanism :: entity \\\\<Rightarrow> bool\\nOperand:   e3 :: event\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_2_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  GeneticEvents :: \"entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  CellDeath :: \"entity \u21d2 bool\"\\n  Occurs :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  CoOccurrence :: \"event \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  DNA :: \"entity\"\\n  Pathways :: \"event \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Force :: \"event \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Compromised :: \"event \u21d2 bool\"\\n  BRCA2Loss :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z w e1 e2 e3 e4. SyntheticLethality x \u2227 GeneticEvents y \u2227 Loss z \u2227 BRCA2 z \u2227 CellDeath w \u2227 Occurs e1 \u2227 Agent e1 x \u2227 CoOccurrence e2 \u2227 Agent e2 y \u2227 Result e3 \u2227 Agent e3 y \u2227 Patient e3 w \u2227 Repair e4 \u2227 Agent e4 y \u2227 Patient e4 DNA \u2227 Pathways e4\"\\n\\n(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3 e4 e5. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cells w \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Force e3 \u2227 Agent e3 x \u2227 Patient e3 w \u2227 Rely e4 \u2227 Agent e4 w \u2227 Repair e5 \u2227 Agent e5 w \u2227 Patient e5 DNA\"\\n\\n(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3 e4. BRCA2Loss x \u2227 SyntheticLethality y \u2227 Cells z \u2227 Mechanism w \u2227 Cause e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Rely e2 \u2227 Agent e2 z \u2227 Patient e2 w \u2227 Repair e3 \u2227 Agent e3 z \u2227 Patient e3 DNA \u2227 Compromised e4 \u2227 Agent e4 x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 SyntheticLethality w\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z w e1 e2 e3 e4. Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 SyntheticLethality w \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Cause e2 \u2227 Agent e2 w \u2227 Patient e2 y \u2227 Rely e3 \u2227 Agent e3 y \u2227 Mechanism e3 \u2227 Repair e4 \u2227 Agent e4 y \u2227 Patient e4 DNA\"\\nproof -\\n  (* From the premise, we have known information about patients, loss of BRCA2, inhibition, PARP1, and synthetic lethality. *)\\n  from asm have \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 SyntheticLethality w\" <ATP>\\n  (* Explanation 3 provides that synthetic lethality in the context of BRCA2 loss implies reliance on a singular mechanism to repair cumulative DNA damage. *)\\n  (* This is captured by the logical relation Implies(I, J). *)\\n  then have \"Rely e3 \u2227 Agent e3 y \u2227 Mechanism e3\" <ATP>\\n  (* Explanation 1 and Explanation 3 together imply that synthetic lethality causes cells to rely on a singular mechanism to repair DNA, and the primary repair pathways are compromised. *)\\n  (* This is captured by the logical relation Implies(I, And(J, K)). *)\\n  then have \"Repair e4 \u2227 Agent e4 y \u2227 Patient e4 DNA\" <ATP>\\n  (* The hypothesis states that patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality. *)\\n  (* We can infer the benefit from the reliance on a singular mechanism to repair DNA damage. *)\\n  then have \"Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: loss of BRCA2 (from Explanatory Sentence 1)\\nC: cell death (from Explanatory Sentence 1)\\nD: inability to repair DNA damage through multiple pathways (from Explanatory Sentence 1)\\nE: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nF: prevention of single strand break repair (from Explanatory Sentence 2)\\nG: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nH: reliance on error-prone non-homologous end joining (from Explanatory Sentence 2)\\nI: synthetic lethality in the context of BRCA2 loss (from Explanatory Sentence 3)\\nJ: reliance on a singular mechanism to repair cumulative DNA damage (from Explanatory Sentence 3)\\nK: primary repair pathways are compromised (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(And(A, B), And(D, C))\\nImplies(A & B, C & D)\\n--------\\nImplies(F, E)\\nImplies(prevention of single strand break repair, PARP inhibitors cause replication-associated double strand breaks)\\n--------\\nImplies(E, And(G, H))\\nImplies(PARP inhibitors cause replication-associated double strand breaks, G & H)\\n--------\\nImplies(I, And(J, K))\\nImplies(synthetic lethality in the context of BRCA2 loss, J & K)\\n--------\\n\\nDerived Implications:\\nImplies(Not(G), Not(F))\\nImplies(Not(reliance on defective homologous recombination repair), Not(prevention of single strand break repair))\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(reliance on defective homologous recombination repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(I, K)\\nImplies(synthetic lethality in the context of BRCA2 loss, primary repair pathways are compromised)\\n--------\\nImplies(E, H)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(F, H)\\nImplies(prevention of single strand break repair, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(primary repair pathways are compromised), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(prevention of single strand break repair))\\n--------\\nImplies(F, G)\\nImplies(prevention of single strand break repair, reliance on defective homologous recombination repair)\\n--------\\nImplies(I, J)\\nImplies(synthetic lethality in the context of BRCA2 loss, reliance on a singular mechanism to repair cumulative DNA damage)\\n--------\\nImplies(E, G)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on defective homologous recombination repair)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(reliance on a singular mechanism to repair cumulative DNA damage), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 4.226630687713623, 'proof tactics': ['Type unification failed: Clash of types \"entity\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Cause :: event \\\\<Rightarrow> bool\\nOperand:   e2 :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_2_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  Occurs :: \"event \u21d2 bool\"\\n  CoOccurrence :: \"entity \u21d2 bool\"\\n  GeneticEvents :: \"entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  CellDeath :: \"entity \u21d2 bool\"\\n  Inability :: \"event \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  DNA :: \"entity \u21d2 bool\"\\n  Damage :: \"entity \u21d2 bool\"\\n  Pathways :: \"entity \u21d2 bool\"\\n  Multiple :: \"entity \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  ReplicationAssociated :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Force :: \"event \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"event \u21d2 entity \u21d2 bool\"\\n  DefectiveHomologousRecombinationRepair :: \"entity \u21d2 bool\"\\n  ErrorProneNonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  BRCA2Loss :: \"entity \u21d2 bool\"\\n  Context :: \"entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Singular :: \"entity \u21d2 bool\"\\n  Cumulative :: \"entity \u21d2 bool\"\\n  PrimaryRepairPathways :: \"entity \u21d2 bool\"\\n  Compromised :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2 e3 e4. SyntheticLethality x \u2227 Occurs e1 \u2227 CoOccurrence y \u2227 GeneticEvents y \u2227 Loss z \u2227 BRCA2 z \u2227 Results e2 \u2227 Agent e2 y \u2227 Patient e2 e3 \u2227 CellDeath e3 \u2227 Inability e4 \u2227 Repair e4 \u2227 Agent e4 y \u2227 Patient e4 u \u2227 DNA u \u2227 Damage u \u2227 Pathways v \u2227 Multiple v\"\\n\\n(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3 e4 e5. PARPInhibitors x \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 ReplicationAssociated y \u2227 DoubleStrandBreaks y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 SingleStrandBreakRepair z \u2227 Force e3 \u2227 Agent e3 x \u2227 Patient e3 w \u2227 Cells w \u2227 Rely e4 \u2227 Agent e4 w \u2227 On e4 v \u2227 DefectiveHomologousRecombinationRepair v \u2227 ErrorProneNonHomologousEndJoining v \u2227 Repair e5 \u2227 Agent e5 w \u2227 Patient e5 u \u2227 DNA u\"\\n\\n(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3 e4. BRCA2Loss x \u2227 Context x \u2227 SyntheticLethality y \u2227 Cause e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Cells z \u2227 Rely e2 \u2227 Agent e2 z \u2227 On e2 v \u2227 Mechanism v \u2227 Singular v \u2227 Repair e3 \u2227 Agent e3 z \u2227 Patient e3 u \u2227 Cumulative u \u2227 DNA u \u2227 Damage u \u2227 PrimaryRepairPathways w \u2227 Compromised w\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z e1 e2 e3 e4. Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells w \u2227 Agent e3 w \u2227 Rely e3 \u2227 On e3 v \u2227 Mechanism v \u2227 Repair e4 \u2227 Agent e4 w \u2227 Patient e4 u \u2227 Damage u \u2227 DNA u \u2227 Cumulative u\"\\nproof -\\n  (* From the premise, we have information about patients with loss of BRCA2 and PARP1 inhibition. *)\\n  from asm have \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z\" <ATP>\\n  \\n  (* Explanation 1 and Explanation 3 are relevant to the hypothesis. *)\\n  (* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\n  (* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised. *)\\n  \\n  (* From Explanation 1, we have the logical relation: Implies(And(A, B), And(D, C)) *)\\n  (* From Explanation 3, we have the logical relation: Implies(And(B, J), I) *)\\n  \\n  (* Since we have Loss y and BRCA2 y, we can infer the co-occurrence of multiple genetic events and the inability to repair DNA damage through multiple pathways. *)\\n  then have \"SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells w \u2227 Agent e3 w \u2227 Rely e3 \u2227 On e3 v \u2227 Mechanism v \u2227 Repair e4 \u2227 Agent e4 w \u2227 Patient e4 u \u2227 Damage u \u2227 DNA u \u2227 Cumulative u\" <ATP>\\n  \\n  (* From Explanation 3, we can infer that in the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage. *)\\n  then have \"Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z\" <ATP>\\n  \\n  (* Combining all the information, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: loss of BRCA2 (from Explanatory Sentence 1)\\nC: cell death (from Explanatory Sentence 1)\\nD: inability to repair DNA damage through multiple pathways (from Explanatory Sentence 1)\\nE: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nF: prevention of single strand break repair (from Explanatory Sentence 2)\\nG: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nH: reliance on error-prone non-homologous end joining (from Explanatory Sentence 2)\\nI: singular mechanism to repair cumulative DNA damage (from Explanatory Sentence 3)\\nJ: primary repair pathways are compromised (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(And(A, B), And(D, C))\\nImplies(A & B, C & D)\\n--------\\nImplies(F, E)\\nImplies(prevention of single strand break repair, PARP inhibitors cause replication-associated double strand breaks)\\n--------\\nImplies(E, And(G, H))\\nImplies(PARP inhibitors cause replication-associated double strand breaks, G & H)\\n--------\\nImplies(And(B, J), I)\\nImplies(B & J, singular mechanism to repair cumulative DNA damage)\\n--------\\n\\nDerived Implications:\\nImplies(Not(G), Not(F))\\nImplies(Not(reliance on defective homologous recombination repair), Not(prevention of single strand break repair))\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(reliance on defective homologous recombination repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(E, H)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(F, H)\\nImplies(prevention of single strand break repair, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(prevention of single strand break repair))\\n--------\\nImplies(F, G)\\nImplies(prevention of single strand break repair, reliance on defective homologous recombination repair)\\n--------\\nImplies(E, G)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on defective homologous recombination repair)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\n'}",
            "3 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 6.335051774978638, 'proof tactics': ['Type unification failed: Clash of types \"entity\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Cause :: event \\\\<Rightarrow> bool\\nOperand:   e2 :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_2_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  Occurs :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  CoOccurrence :: \"entity \u21d2 bool\"\\n  GeneticEvents :: \"entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n  Death :: \"event \u21d2 bool\"\\n  Cell :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Inability :: \"event \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  Damage :: \"entity \u21d2 bool\"\\n  DNA :: \"entity \u21d2 bool\"\\n  Pathways :: \"entity \u21d2 bool\"\\n  Multiple :: \"entity \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Breaks :: \"entity \u21d2 bool\"\\n  DoubleStrand :: \"entity \u21d2 bool\"\\n  ReplicationAssociated :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  SingleStrand :: \"entity \u21d2 bool\"\\n  Force :: \"event \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"entity \u21d2 entity \u21d2 bool\"\\n  Defective :: \"entity \u21d2 bool\"\\n  HomologousRecombination :: \"entity \u21d2 bool\"\\n  ErrorProne :: \"entity \u21d2 bool\"\\n  NonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  BRCA2Loss :: \"entity \u21d2 bool\"\\n  Context :: \"entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Singular :: \"entity \u21d2 bool\"\\n  Cumulative :: \"entity \u21d2 bool\"\\n  Primary :: \"entity \u21d2 bool\"\\n  Compromised :: \"event \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2 e3 e4 u v. SyntheticLethality x \u2227 Occurs e1 \u2227 Agent e1 x \u2227 CoOccurrence y \u2227 GeneticEvents y \u2227 Loss z \u2227 BRCA2 z \u2227 Results e2 \u2227 Agent e2 y \u2227 Death e3 \u2227 Cell e3 \u2227 Patient e2 z \u2227 Inability e4 \u2227 Repair e4 \u2227 Agent e4 y \u2227 Damage u \u2227 DNA u \u2227 Patient e4 u \u2227 Pathways v \u2227 Multiple v \u2227 Through e4 v\"\\n\\n(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3 e4 e5 u v. PARPInhibitors x \u2227 Cause e1 \u2227 Agent e1 x \u2227 Breaks y \u2227 DoubleStrand y \u2227 ReplicationAssociated y \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Repair e2 \u2227 SingleStrand z \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Force e3 \u2227 Agent e3 x \u2227 Cells w \u2227 Patient e3 w \u2227 Rely e4 \u2227 Agent e4 w \u2227 Repair e5 \u2227 DNA u \u2227 Patient e5 u \u2227 On w v \u2227 Defective v \u2227 HomologousRecombination v \u2227 ErrorProne v \u2227 NonHomologousEndJoining v\"\\n\\n(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3 e4 u v. BRCA2Loss x \u2227 Context x \u2227 SyntheticLethality y \u2227 Cause e1 \u2227 Agent e1 y \u2227 Cells z \u2227 Patient e1 z \u2227 Rely e2 \u2227 Agent e2 z \u2227 Mechanism w \u2227 Singular w \u2227 On z w \u2227 Repair e3 \u2227 Agent e3 z \u2227 Damage u \u2227 Cumulative u \u2227 DNA u \u2227 Patient e3 u \u2227 Pathways v \u2227 Primary v \u2227 Compromised e4 \u2227 Agent e4 v\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z e1 e2 e3 e4. Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells w \u2227 Agent e3 w \u2227 Rely e3 \u2227 Mechanism v \u2227 On w v \u2227 Repair e4 \u2227 Agent e4 w \u2227 Damage u \u2227 DNA u \u2227 Patient e4 u\"\\nproof -\\n  (* From the premise, we have information about patients with loss of BRCA2 and PARP1 inhibition. *)\\n  from asm have \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z\" <ATP>\\n  \\n  (* Explanation 1 and Explanation 3 are relevant to the hypothesis. *)\\n  (* Explanation 1 provides the context of synthetic lethality with BRCA2 loss leading to cell death due to inability to repair DNA damage. *)\\n  (* Explanation 3 states that in the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage. *)\\n  \\n  (* Using Explanation 3, we can infer that BRCA2 loss and compromised primary repair pathways lead to reliance on a singular mechanism. *)\\n  have \"BRCA2Loss y \u2227 Primary v \u2227 Compromised e4 \u27f6 SingularMechanism v\" <ATP>\\n  \\n  (* From Explanation 2, PARP inhibitors cause replication-associated double strand breaks, leading to reliance on defective repair mechanisms. *)\\n  have \"PARPInhibitors z \u27f6 (DefectiveRepairMechanism \u2227 ErrorProneRepairMechanism)\" <ATP>\\n  \\n  (* Combining these, we can infer that patients with BRCA2 loss and PARP1 inhibition benefit from synthetic lethality. *)\\n  have \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u27f6 BenefitFromSyntheticLethality\" <ATP>\\n  \\n  (* Therefore, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: loss of BRCA2 (from Explanatory Sentence 1)\\nC: cell death (from Explanatory Sentence 1)\\nD: inability to repair DNA damage through multiple pathways (from Explanatory Sentence 1)\\nE: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nF: prevention of single strand break repair (from Explanatory Sentence 2)\\nG: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nH: reliance on error-prone non-homologous end joining (from Explanatory Sentence 2)\\nI: singular mechanism to repair cumulative DNA damage (from Explanatory Sentence 3)\\nJ: primary repair pathways are compromised (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(And(A, B), And(D, C))\\nImplies(A & B, C & D)\\n--------\\nImplies(F, E)\\nImplies(prevention of single strand break repair, PARP inhibitors cause replication-associated double strand breaks)\\n--------\\nImplies(E, And(G, H))\\nImplies(PARP inhibitors cause replication-associated double strand breaks, G & H)\\n--------\\nImplies(And(B, J), I)\\nImplies(B & J, singular mechanism to repair cumulative DNA damage)\\n--------\\n\\nDerived Implications:\\nImplies(Not(G), Not(F))\\nImplies(Not(reliance on defective homologous recombination repair), Not(prevention of single strand break repair))\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(reliance on defective homologous recombination repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(E, H)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(F, H)\\nImplies(prevention of single strand break repair, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(prevention of single strand break repair))\\n--------\\nImplies(F, G)\\nImplies(prevention of single strand break repair, reliance on defective homologous recombination repair)\\n--------\\nImplies(E, G)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on defective homologous recombination repair)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\n'}",
            "4 iteration: {'syntactic validity': True, 'error code': '(* Explanation 3 states that in the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage. *)\\n(* This aligns with the logical relation Implies(And(B, J), I), where B is loss of BRCA2 and J is primary repair pathways are compromised. *)\\n(* We can infer that cells rely on a singular mechanism to repair cumulative DNA damage. *)\\nthen have \"Rely e3 \u2227 Agent e3 y \u2227 Mechanism e3 \u2227 Repair e4 \u2227 Agent e4 y \u2227 Patient e4 cumulativeDamage \u2227 To cumulativeDamage DNA\" sledgehammer', 'solving time': 103.25230646133423, 'proof tactics': [], 'code': 'theory clinical_2_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  GeneticEvents :: \"entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Occurs :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  CoOccurrence :: \"event \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  Through :: \"entity \u21d2 entity \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Force :: \"event \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"event \u21d2 entity \u21d2 bool\"\\n  BRCA2Loss :: \"entity \u21d2 bool\"\\n  Compromised :: \"event \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Mechanism :: \"event \u21d2 bool\"\\n  To :: \"entity \u21d2 entity \u21d2 bool\"\\n  cumulativeDamage :: \"entity\"\\n  DNA :: \"entity\"\\n\\n(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2 e3 e4. SyntheticLethality x \u2227 GeneticEvents y \u2227 Loss z \u2227 BRCA2 z \u2227 Occurs e1 \u2227 Agent e1 x \u2227 CoOccurrence e2 \u2227 Agent e2 y \u2227 Result e3 \u2227 Agent e3 y \u2227 Patient e3 cellDeath \u2227 Repair e4 \u2227 Agent e4 y \u2227 Patient e4 DNA \u2227 Through DNA multiplePathways\"\\n\\n(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3 e4 e5. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cells w \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Force e3 \u2227 Agent e3 x \u2227 Patient e3 w \u2227 Rely e4 \u2227 Agent e4 w \u2227 On e4 defectiveHomologousRecombinationRepair \u2227 Repair e5 \u2227 Agent e5 w \u2227 Patient e5 DNA\"\\n\\n(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2 e3 e4. BRCA2Loss x \u2227 SyntheticLethality y \u2227 Cells z \u2227 Cause e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Rely e2 \u2227 Agent e2 z \u2227 On e2 singularMechanism \u2227 Repair e3 \u2227 Agent e3 z \u2227 Patient e3 cumulativeDNADamage \u2227 Compromised e4 \u2227 Agent e4 primaryRepairPathways\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 SyntheticLethality w\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z w e1 e2 e3 e4. Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 SyntheticLethality w \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 Cause e2 \u2227 Agent e2 w \u2227 Patient e2 y \u2227 Rely e3 \u2227 Agent e3 y \u2227 Mechanism e3 \u2227 Repair e4 \u2227 Agent e4 y \u2227 Patient e4 cumulativeDamage \u2227 To cumulativeDamage DNA\"\\nproof -\\n  (* From the premise, we have known information about patients, loss of BRCA2, PARP1 inhibition, and synthetic lethality. *)\\n  from asm have \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 SyntheticLethality w\" <ATP>\\n  (* Explanation 3 states that in the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage. *)\\n  (* This aligns with the logical relation Implies(And(B, J), I), where B is loss of BRCA2 and J is primary repair pathways are compromised. *)\\n  (* We can infer that cells rely on a singular mechanism to repair cumulative DNA damage. *)\\n  then have \"Rely e3 \u2227 Agent e3 y \u2227 Mechanism e3 \u2227 Repair e4 \u2227 Agent e4 y \u2227 Patient e4 cumulativeDamage \u2227 To cumulativeDamage DNA\" <ATP>\\n  (* The hypothesis states that patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality. *)\\n  (* We can conclude that there is a benefit to patients from PARP1 inhibition. *)\\n  then have \"Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: loss of BRCA2 (from Explanatory Sentence 1)\\nC: cell death (from Explanatory Sentence 1)\\nD: inability to repair DNA damage through multiple pathways (from Explanatory Sentence 1)\\nE: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nF: prevention of single strand break repair (from Explanatory Sentence 2)\\nG: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nH: reliance on error-prone non-homologous end joining (from Explanatory Sentence 2)\\nI: singular mechanism to repair cumulative DNA damage (from Explanatory Sentence 3)\\nJ: primary repair pathways are compromised (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(And(A, B), And(D, C))\\nImplies(A & B, C & D)\\n--------\\nImplies(F, E)\\nImplies(prevention of single strand break repair, PARP inhibitors cause replication-associated double strand breaks)\\n--------\\nImplies(E, And(G, H))\\nImplies(PARP inhibitors cause replication-associated double strand breaks, G & H)\\n--------\\nImplies(And(B, J), I)\\nImplies(B & J, singular mechanism to repair cumulative DNA damage)\\n--------\\n\\nDerived Implications:\\nImplies(Not(G), Not(F))\\nImplies(Not(reliance on defective homologous recombination repair), Not(prevention of single strand break repair))\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(reliance on defective homologous recombination repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(E, H)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(F, H)\\nImplies(prevention of single strand break repair, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(prevention of single strand break repair))\\n--------\\nImplies(F, G)\\nImplies(prevention of single strand break repair, reliance on defective homologous recombination repair)\\n--------\\nImplies(E, G)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on defective homologous recombination repair)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\n'}",
            "5 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 6.620243310928345, 'proof tactics': ['Type unification failed: Clash of types \"entity\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Cause :: event \\\\<Rightarrow> bool\\nOperand:   e2 :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_2_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  Occurs :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  CoOccurrence :: \"entity \u21d2 bool\"\\n  GeneticEvents :: \"entity \u21d2 bool\"\\n  Multiple :: \"entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n  Death :: \"event \u21d2 bool\"\\n  Cell :: \"event \u21d2 bool\"\\n  Inability :: \"event \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  DNA :: \"entity \u21d2 bool\"\\n  Damage :: \"entity \u21d2 bool\"\\n  Pathways :: \"entity \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Breaks :: \"entity \u21d2 bool\"\\n  DoubleStrand :: \"entity \u21d2 bool\"\\n  ReplicationAssociated :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Force :: \"event \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  HomologousRecombinationRepair :: \"event \u21d2 bool\"\\n  Defective :: \"event \u21d2 bool\"\\n  NonHomologousEndJoining :: \"event \u21d2 bool\"\\n  ErrorProne :: \"event \u21d2 bool\"\\n  BRCA2Loss :: \"entity \u21d2 bool\"\\n  Context :: \"entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Singular :: \"entity \u21d2 bool\"\\n  Cumulative :: \"entity \u21d2 bool\"\\n  Primary :: \"entity \u21d2 bool\"\\n  Compromised :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Reliance :: \"event \u21d2 bool\"\\n  Increased :: \"event \u21d2 bool\"\\n  Mechanisms :: \"entity \u21d2 bool\"\\n  Alternative :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2 e3 e4. SyntheticLethality x \u2227 Occurs e1 \u2227 Agent e1 x \u2227 CoOccurrence y \u2227 GeneticEvents y \u2227 Multiple y \u2227 Loss z \u2227 BRCA2 z \u2227 Results e2 \u2227 Agent e2 y \u2227 Death e3 \u2227 Cell e3 \u2227 Inability e4 \u2227 Repair e4 \u2227 DNA z \u2227 Damage z \u2227 Pathways y \u2227 Multiple y\"\\n\\n(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2 e3 e4 e5. PARPInhibitors x \u2227 Cause e1 \u2227 Agent e1 x \u2227 Breaks y \u2227 DoubleStrand y \u2227 ReplicationAssociated y \u2227 Prevent e2 \u2227 SingleStrandBreakRepair z \u2227 Force e3 \u2227 Cells z \u2227 Rely e4 \u2227 Agent e4 z \u2227 Repair e5 \u2227 HomologousRecombinationRepair e5 \u2227 Defective e5 \u2227 NonHomologousEndJoining e5 \u2227 ErrorProne e5 \u2227 DNA z\"\\n\\n(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2 e3 e4 e5. BRCA2Loss x \u2227 Context x \u2227 SyntheticLethality y \u2227 Cause e1 \u2227 Agent e1 y \u2227 Cells z \u2227 Rely e2 \u2227 Agent e2 z \u2227 Mechanism y \u2227 Singular y \u2227 Repair e3 \u2227 DNA z \u2227 Damage z \u2227 Cumulative z \u2227 Pathways y \u2227 Primary y \u2227 Compromised y \u2227 Lead e4 \u2227 Reliance e5 \u2227 Increased e5 \u2227 Mechanisms y \u2227 Alternative y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z e1 e2 e3. Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells x \u2227 Rely e3 \u2227 Agent e3 x \u2227 Mechanism y \u2227 Singular y \u2227 Repair e3 \u2227 Damage y \u2227 DNA y \u2227 Cumulative y\"\\nproof -\\n  (* From the premise, we have known information about patients, loss of BRCA2, and PARP1 inhibition. *)\\n  from asm have \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z\" <ATP>\\n  (* Explanation 3 provides a logical relation Implies(I, And(J, K, L)), which implies synthetic lethality in the context of BRCA2 loss leads to reliance on a singular mechanism, compromised primary pathways, and increased reliance on alternative mechanisms. *)\\n  (* We can use the derived implications Implies(I, J) and Implies(I, L) to infer reliance on a singular mechanism and increased reliance on alternative mechanisms. *)\\n  have \"SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells x \u2227 Rely e3 \u2227 Agent e3 x \u2227 Mechanism y \u2227 Singular y \u2227 Repair e3 \u2227 Damage y \u2227 DNA y \u2227 Cumulative y\" <ATP>\\n  (* From the above, we can infer that patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality. *)\\n  then have \"Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: loss of BRCA2 (from Explanatory Sentence 1)\\nC: cell death (from Explanatory Sentence 1)\\nD: inability to repair DNA damage through multiple pathways (from Explanatory Sentence 1)\\nE: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nF: prevention of single strand break repair (from Explanatory Sentence 2)\\nG: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nH: reliance on error-prone non-homologous end joining (from Explanatory Sentence 2)\\nI: synthetic lethality in the context of BRCA2 loss (from Explanatory Sentence 3)\\nJ: reliance on a singular mechanism to repair cumulative DNA damage (from Explanatory Sentence 3)\\nK: primary repair pathways are compromised (from Explanatory Sentence 3)\\nL: increased reliance on alternative repair mechanisms (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(And(A, B), And(D, C))\\nImplies(A & B, C & D)\\n--------\\nImplies(E, And(F, Or(G, H)))\\nImplies(PARP inhibitors cause replication-associated double strand breaks, F & (G | H))\\n--------\\nImplies(I, And(J, K, L))\\nImplies(synthetic lethality in the context of BRCA2 loss, J & K & L)\\n--------\\n\\nDerived Implications:\\nImplies(I, K)\\nImplies(synthetic lethality in the context of BRCA2 loss, primary repair pathways are compromised)\\n--------\\nImplies(Not(F), Not(E))\\nImplies(Not(prevention of single strand break repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(primary repair pathways are compromised), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\nImplies(I, J)\\nImplies(synthetic lethality in the context of BRCA2 loss, reliance on a singular mechanism to repair cumulative DNA damage)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(reliance on a singular mechanism to repair cumulative DNA damage), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\nImplies(E, F)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, prevention of single strand break repair)\\n--------\\nImplies(Not(L), Not(I))\\nImplies(Not(increased reliance on alternative repair mechanisms), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\nImplies(I, L)\\nImplies(synthetic lethality in the context of BRCA2 loss, increased reliance on alternative repair mechanisms)\\n--------\\n'}",
            "6 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 4.270251274108887, 'proof tactics': ['Type unification failed: Clash of types \"entity\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Cause :: event \\\\<Rightarrow> bool\\nOperand:   e2 :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_2_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  Occurs :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  CoOccurrence :: \"entity \u21d2 bool\"\\n  GeneticEvents :: \"entity \u21d2 bool\"\\n  Multiple :: \"entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n  Death :: \"event \u21d2 bool\"\\n  Cell :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Inability :: \"event \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  DNA :: \"entity \u21d2 bool\"\\n  Damage :: \"entity \u21d2 bool\"\\n  Pathways :: \"entity \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Breaks :: \"entity \u21d2 bool\"\\n  DoubleStrand :: \"entity \u21d2 bool\"\\n  ReplicationAssociated :: \"entity \u21d2 bool\"\\n  Preventing :: \"event \u21d2 bool\"\\n  SingleStrand :: \"entity \u21d2 bool\"\\n  Break :: \"entity \u21d2 bool\"\\n  Force :: \"event \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  HomologousRecombination :: \"event \u21d2 bool\"\\n  Defective :: \"event \u21d2 bool\"\\n  NonHomologousEndJoining :: \"event \u21d2 bool\"\\n  ErrorProne :: \"event \u21d2 bool\"\\n  Context :: \"entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Singular :: \"entity \u21d2 bool\"\\n  Cumulative :: \"event \u21d2 bool\"\\n  Primary :: \"entity \u21d2 bool\"\\n  Compromised :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Reliance :: \"event \u21d2 bool\"\\n  Increased :: \"event \u21d2 bool\"\\n  Alternative :: \"event \u21d2 bool\"\\n  RepairMechanisms :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2 e3 e4 w v. SyntheticLethality x \u2227 Occurs e1 \u2227 Agent e1 x \u2227 CoOccurrence y \u2227 GeneticEvents y \u2227 Multiple y \u2227 Loss z \u2227 BRCA2 z \u2227 Results e2 \u2227 Agent e2 y \u2227 Death e3 \u2227 Cell e3 \u2227 Patient e2 z \u2227 Inability e4 \u2227 Repair e4 \u2227 DNA w \u2227 Damage w \u2227 Pathways v \u2227 Multiple v \u2227 Patient e4 w\"\\n\\n(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2 e3 e4 e5 w v. PARPInhibitors x \u2227 Cause e1 \u2227 Agent e1 x \u2227 Breaks y \u2227 DoubleStrand y \u2227 ReplicationAssociated y \u2227 Patient e1 y \u2227 Preventing e2 \u2227 Repair e2 \u2227 SingleStrand z \u2227 Break z \u2227 Patient e2 z \u2227 Force e3 \u2227 Cells w \u2227 Agent e3 w \u2227 Rely e4 \u2227 Agent e4 w \u2227 Repair e5 \u2227 HomologousRecombination e5 \u2227 Defective e5 \u2227 NonHomologousEndJoining e5 \u2227 ErrorProne e5 \u2227 DNA v \u2227 Patient e5 v\"\\n\\n(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w v e1 e2 e3 e4 e5 u t s. BRCA2 x \u2227 Loss x \u2227 Context y \u2227 In y x \u2227 SyntheticLethality z \u2227 Cause e1 \u2227 Agent e1 z \u2227 Cells w \u2227 Rely e2 \u2227 Agent e2 w \u2227 Mechanism v \u2227 Singular v \u2227 Repair e3 \u2227 Cumulative e3 \u2227 DNA u \u2227 Damage u \u2227 Patient e3 u \u2227 Pathways t \u2227 Primary t \u2227 Compromised t \u2227 Lead e4 \u2227 Reliance e5 \u2227 Increased e5 \u2227 Alternative e5 \u2227 RepairMechanisms s \u2227 Patient e5 s\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z e1 e2 e3 w v. Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells x \u2227 Rely e3 \u2227 Agent e3 x \u2227 Mechanism w \u2227 Singular w \u2227 Repair e3 \u2227 Damage v \u2227 Cumulative v \u2227 DNA v \u2227 Patient e3 v\"\\nproof -\\n  (* From the premise, we have known information about patients, loss of BRCA2, and PARP1 inhibition. *)\\n  from asm have \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z\" <ATP>\\n  \\n  (* Explanation 3 provides a logical relation: Implies(And(B, J), And(I, K)) *)\\n  (* This means that if there is a loss of BRCA2 and primary repair pathways are compromised, *)\\n  (* then there is a reliance on a singular mechanism to repair cumulative DNA damage and increased reliance on alternative repair mechanisms. *)\\n  (* From Explanation 3, we know that in the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism. *)\\n  have \"BRCA2 y \u2227 Loss y \u27f6 (Singular w \u2227 Mechanism w \u2227 Rely e3 \u2227 Repair e3 \u2227 Cumulative v \u2227 Damage v \u2227 DNA v \u2227 Patient e3 v)\" <ATP>\\n  \\n  (* Explanation 2 provides that PARP inhibitors cause replication-associated double strand breaks, *)\\n  (* which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining. *)\\n  have \"PARPInhibitors z \u27f6 (Rely e3 \u2227 Repair e3)\" <ATP>\\n  \\n  (* Combining the above, we can infer that patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality. *)\\n  (* This is because synthetic lethality causes cells to rely on a singular mechanism to repair cumulative damage to DNA. *)\\n  then have \"Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells x \u2227 Rely e3 \u2227 Agent e3 x \u2227 Mechanism w \u2227 Singular w \u2227 Repair e3 \u2227 Damage v \u2227 Cumulative v \u2227 DNA v \u2227 Patient e3 v\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: loss of BRCA2 (from Explanatory Sentence 1)\\nC: cell death (from Explanatory Sentence 1)\\nD: inability to repair DNA damage through multiple pathways (from Explanatory Sentence 1)\\nE: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nF: prevention of single strand break repair (from Explanatory Sentence 2)\\nG: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nH: reliance on error-prone non-homologous end joining (from Explanatory Sentence 2)\\nI: singular mechanism to repair cumulative DNA damage (from Explanatory Sentence 3)\\nJ: primary repair pathways are compromised (from Explanatory Sentence 3)\\nK: increased reliance on alternative repair mechanisms (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(And(A, B), And(D, C))\\nImplies(A & B, C & D)\\n--------\\nImplies(E, And(F, Or(G, H)))\\nImplies(PARP inhibitors cause replication-associated double strand breaks, F & (G | H))\\n--------\\nImplies(And(B, J), And(I, K))\\nImplies(B & J, I & K)\\n--------\\n\\nDerived Implications:\\nImplies(Not(F), Not(E))\\nImplies(Not(prevention of single strand break repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(E, F)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, prevention of single strand break repair)\\n--------\\n'}",
            "7 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 6.109914541244507, 'proof tactics': ['Type unification failed: Clash of types \"entity\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Cause :: event \\\\<Rightarrow> bool\\nOperand:   e2 :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_2_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  Occurs :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  CoOccurrence :: \"entity \u21d2 bool\"\\n  GeneticEvents :: \"entity \u21d2 bool\"\\n  Multiple :: \"entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Results :: \"event \u21d2 bool\"\\n  Death :: \"event \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Inability :: \"event \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  DNA :: \"entity \u21d2 bool\"\\n  Damage :: \"entity \u21d2 bool\"\\n  Pathways :: \"entity \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Breaks :: \"entity \u21d2 bool\"\\n  DoubleStrand :: \"entity \u21d2 bool\"\\n  ReplicationAssociated :: \"entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  SingleStrand :: \"entity \u21d2 bool\"\\n  Break :: \"entity \u21d2 bool\"\\n  Force :: \"event \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  HomologousRecombination :: \"event \u21d2 bool\"\\n  Defective :: \"event \u21d2 bool\"\\n  NonHomologousEndJoining :: \"event \u21d2 bool\"\\n  ErrorProne :: \"event \u21d2 bool\"\\n  Context :: \"entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Singular :: \"entity \u21d2 bool\"\\n  Cumulative :: \"entity \u21d2 bool\"\\n  Primary :: \"entity \u21d2 bool\"\\n  Compromised :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Reliance :: \"event \u21d2 bool\"\\n  Increased :: \"event \u21d2 bool\"\\n  Mechanisms :: \"entity \u21d2 bool\"\\n  Alternative :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2 e3 e4. SyntheticLethality x \u2227 Occurs e1 \u2227 Agent e1 x \u2227 CoOccurrence y \u2227 GeneticEvents y \u2227 Multiple y \u2227 Loss z \u2227 BRCA2 z \u2227 Results e2 \u2227 Agent e2 y \u2227 Death e3 \u2227 Cells z \u2227 Patient e3 z \u2227 Inability e4 \u2227 Repair e4 \u2227 DNA w \u2227 Damage w \u2227 Pathways v \u2227 Multiple v\"\\n\\n(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2 e3 e4 e5. PARPInhibitors x \u2227 Cause e1 \u2227 Agent e1 x \u2227 Breaks y \u2227 DoubleStrand y \u2227 ReplicationAssociated y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Repair e3 \u2227 SingleStrand z \u2227 Break z \u2227 Force e3 \u2227 Agent e3 x \u2227 Cells w \u2227 Rely e4 \u2227 Agent e4 w \u2227 Repair e5 \u2227 HomologousRecombination e5 \u2227 Defective e5 \u2227 NonHomologousEndJoining e5 \u2227 ErrorProne e5 \u2227 DNA v\"\\n\\n(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2 e3 e4 e5. BRCA2 x \u2227 Loss x \u2227 Context y \u2227 SyntheticLethality z \u2227 Cause e1 \u2227 Agent e1 z \u2227 Cells w \u2227 Rely e2 \u2227 Agent e2 w \u2227 Mechanism v \u2227 Singular v \u2227 Repair e3 \u2227 DNA u \u2227 Damage u \u2227 Cumulative u \u2227 Pathways t \u2227 Primary t \u2227 Compromised t \u2227 Lead e4 \u2227 Agent e4 t \u2227 Reliance e5 \u2227 Increased e5 \u2227 Mechanisms s \u2227 Alternative s\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z e1 e2 e3. Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells y \u2227 Rely e3 \u2227 Agent e3 y \u2227 Mechanism z \u2227 Singular z \u2227 Repair e3 \u2227 Damage w \u2227 Cumulative w \u2227 DNA w\"\\nproof -\\n  (* From the premise, we have information about patients, loss of BRCA2, and PARP1 inhibition. *)\\n  from asm have \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z\" <ATP>\\n  (* Explanation 3 provides a logical relation Implies(I, J), which states that synthetic lethality in the context of BRCA2 loss implies reliance on a singular mechanism to repair cumulative DNA damage. *)\\n  (* Since we have Loss y and BRCA2 y, we can infer synthetic lethality in the context of BRCA2 loss. *)\\n  then have \"SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells y \u2227 Rely e3 \u2227 Agent e3 y \u2227 Mechanism z \u2227 Singular z \u2227 Repair e3 \u2227 Damage w \u2227 Cumulative w \u2227 DNA w\" <ATP>\\n  (* Explanation 3 also implies that synthetic lethality leads to increased reliance on alternative repair mechanisms. *)\\n  (* This increased reliance can be seen as a benefit in the context of PARP1 inhibition. *)\\n  then have \"Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z\" <ATP>\\n  (* Combining all the information, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: loss of BRCA2 (from Explanatory Sentence 1)\\nC: cell death (from Explanatory Sentence 1)\\nD: inability to repair DNA damage through multiple pathways (from Explanatory Sentence 1)\\nE: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nF: prevention of single strand break repair (from Explanatory Sentence 2)\\nG: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nH: reliance on error-prone non-homologous end joining (from Explanatory Sentence 2)\\nI: synthetic lethality in the context of BRCA2 loss (from Explanatory Sentence 3)\\nJ: reliance on a singular mechanism to repair cumulative DNA damage (from Explanatory Sentence 3)\\nK: primary repair pathways are compromised (from Explanatory Sentence 3)\\nL: increased reliance on alternative repair mechanisms (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(And(A, B), And(D, C))\\nImplies(A & B, C & D)\\n--------\\nImplies(E, And(F, Or(G, H)))\\nImplies(PARP inhibitors cause replication-associated double strand breaks, F & (G | H))\\n--------\\nImplies(I, And(J, And(K, L)))\\nImplies(synthetic lethality in the context of BRCA2 loss, J & K & L)\\n--------\\n\\nDerived Implications:\\nImplies(I, K)\\nImplies(synthetic lethality in the context of BRCA2 loss, primary repair pathways are compromised)\\n--------\\nImplies(Not(F), Not(E))\\nImplies(Not(prevention of single strand break repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(primary repair pathways are compromised), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\nImplies(I, J)\\nImplies(synthetic lethality in the context of BRCA2 loss, reliance on a singular mechanism to repair cumulative DNA damage)\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(reliance on a singular mechanism to repair cumulative DNA damage), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\nImplies(E, F)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, prevention of single strand break repair)\\n--------\\nImplies(Not(L), Not(I))\\nImplies(Not(increased reliance on alternative repair mechanisms), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\nImplies(I, L)\\nImplies(synthetic lethality in the context of BRCA2 loss, increased reliance on alternative repair mechanisms)\\n--------\\n'}",
            "8 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 6.9498677253723145, 'proof tactics': ['Type unification failed: Clash of types \"entity\" and \"event\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Cause :: event \\\\<Rightarrow> bool\\nOperand:   e2 :: entity\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_2_8\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  Occurs :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  GeneticEvents :: \"entity \u21d2 bool\"\\n  CoOccurrence :: \"entity \u21d2 bool\"\\n  Loss :: \"entity \u21d2 bool\"\\n  BRCA2 :: \"entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  Death :: \"event \u21d2 bool\"\\n  Inability :: \"event \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  Damage :: \"entity \u21d2 bool\"\\n  DNA :: \"entity \u21d2 bool\"\\n  Pathways :: \"entity \u21d2 bool\"\\n  Multiple :: \"entity \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  ReplicationAssociated :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Force :: \"event \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  HomologousRecombinationRepair :: \"entity \u21d2 bool\"\\n  Defective :: \"entity \u21d2 bool\"\\n  NonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  ErrorProne :: \"entity \u21d2 bool\"\\n  BRCA2Loss :: \"entity \u21d2 bool\"\\n  Context :: \"entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Singular :: \"entity \u21d2 bool\"\\n  Cumulative :: \"entity \u21d2 bool\"\\n  Primary :: \"entity \u21d2 bool\"\\n  Compromised :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Reliance :: \"entity \u21d2 bool\"\\n  Increased :: \"entity \u21d2 bool\"\\n  Alternative :: \"entity \u21d2 bool\"\\n  Mechanisms :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  Inhibition :: \"entity \u21d2 bool\"\\n  PARP1 :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2 e3. SyntheticLethality x \u2227 Occurs e1 \u2227 Agent e1 x \u2227 GeneticEvents y \u2227 CoOccurrence y \u2227 Loss z \u2227 BRCA2 z \u2227 Result e2 \u2227 Agent e2 y \u2227 Death e3 \u2227 Agent e3 z \u2227 Inability e3 \u2227 Repair e3 \u2227 Damage z \u2227 DNA z \u2227 Pathways y \u2227 Multiple y\"\\n\\n(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2 e3 e4 e5. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 ReplicationAssociated y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 SingleStrandBreakRepair z \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Force e3 \u2227 Cells z \u2227 Rely e4 \u2227 Agent e4 z \u2227 Repair e5 \u2227 DNA y \u2227 HomologousRecombinationRepair y \u2227 Defective y \u2227 NonHomologousEndJoining y \u2227 ErrorProne y\"\\n\\n(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2 e3 e4. BRCA2Loss x \u2227 Context x \u2227 SyntheticLethality y \u2227 Cause e1 \u2227 Agent e1 y \u2227 Cells z \u2227 Rely e2 \u2227 Agent e2 z \u2227 Mechanism y \u2227 Singular y \u2227 Repair e3 \u2227 Damage z \u2227 DNA z \u2227 Cumulative z \u2227 Pathways y \u2227 Primary y \u2227 Compromised y \u2227 Lead e4 \u2227 Reliance z \u2227 Increased z \u2227 Mechanisms y \u2227 Alternative y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 Cells x\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z e1 e2 e3. Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z \u2227 SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells x \u2227 Rely e3 \u2227 Agent e3 x \u2227 Mechanism y \u2227 Singular y \u2227 Repair e3 \u2227 Damage y \u2227 DNA y \u2227 Cumulative y\"\\nproof -\\n  (* From the premise, we have information about patients, loss of BRCA2, and PARP1 inhibition. *)\\n  from asm have \"Patients x \u2227 Loss y \u2227 BRCA2 y \u2227 Inhibition z \u2227 PARP1 z \u2227 Cells x\" <ATP>\\n  \\n  (* Explanation 3 provides a logical relation: Implies(I, J), which means synthetic lethality in the context of BRCA2 loss implies reliance on a singular mechanism to repair cumulative DNA damage. *)\\n  (* We can use this to infer that synthetic lethality causes cells to rely on a singular mechanism. *)\\n  have \"SyntheticLethality e2 \u2227 Cause e2 e3 \u2227 Cells x \u2227 Rely e3 \u2227 Agent e3 x \u2227 Mechanism y \u2227 Singular y \u2227 Repair e3 \u2227 Damage y \u2227 DNA y \u2227 Cumulative y\" <ATP>\\n  \\n  (* Explanation 1 and Explanation 2 are not directly needed to infer the hypothesis, as Explanation 3 provides the necessary link between BRCA2 loss and synthetic lethality. *)\\n  \\n  (* Therefore, we can conclude that patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality. *)\\n  then have \"Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 z\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: loss of BRCA2 (from Explanatory Sentence 1)\\nC: cell death (from Explanatory Sentence 1)\\nD: inability to repair DNA damage through multiple pathways (from Explanatory Sentence 1)\\nE: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nF: prevention of single strand break repair (from Explanatory Sentence 2)\\nG: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nH: reliance on error-prone non-homologous end joining (from Explanatory Sentence 2)\\nI: synthetic lethality in the context of BRCA2 loss (from Explanatory Sentence 3)\\nJ: reliance on a singular mechanism to repair cumulative DNA damage (from Explanatory Sentence 3)\\nK: primary repair pathways are compromised (from Explanatory Sentence 3)\\nL: increased reliance on alternative repair mechanisms (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(And(A, B), And(D, C))\\nImplies(A & B, C & D)\\n--------\\nImplies(E, And(F, And(G, H)))\\nImplies(PARP inhibitors cause replication-associated double strand breaks, F & G & H)\\n--------\\nImplies(I, And(J, And(K, L)))\\nImplies(synthetic lethality in the context of BRCA2 loss, J & K & L)\\n--------\\n\\nDerived Implications:\\nImplies(Not(G), Not(E))\\nImplies(Not(reliance on defective homologous recombination repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(I, K)\\nImplies(synthetic lethality in the context of BRCA2 loss, primary repair pathways are compromised)\\n--------\\nImplies(Not(F), Not(E))\\nImplies(Not(prevention of single strand break repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(E, H)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(Not(K), Not(I))\\nImplies(Not(primary repair pathways are compromised), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\nImplies(E, G)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on defective homologous recombination repair)\\n--------\\nImplies(I, J)\\nImplies(synthetic lethality in the context of BRCA2 loss, reliance on a singular mechanism to repair cumulative DNA damage)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(Not(J), Not(I))\\nImplies(Not(reliance on a singular mechanism to repair cumulative DNA damage), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\nImplies(E, F)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, prevention of single strand break repair)\\n--------\\nImplies(Not(L), Not(I))\\nImplies(Not(increased reliance on alternative repair mechanisms), Not(synthetic lethality in the context of BRCA2 loss))\\n--------\\nImplies(I, L)\\nImplies(synthetic lethality in the context of BRCA2 loss, increased reliance on alternative repair mechanisms)\\n--------\\n'}",
            "9 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 0, 'proof tactics': [], 'code': 'theory clinical_2_9\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  GeneticEvents :: \"entity \u21d2 bool\"\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  Occurs :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  CoOccurrence :: \"event \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  InabilityToRepair :: \"event \u21d2 bool\"\\n  DNA :: \"entity \u21d2 bool\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  MultiplePathways :: \"entity \u21d2 bool\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Force :: \"event \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"event \u21d2 entity \u21d2 bool\"\\n  DefectiveHomologousRecombinationRepair :: \"entity \u21d2 bool\"\\n  ErrorProneNonHomologousEndJoining :: \"entity \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  BRCA2Loss :: \"entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  CumulativeDNADamage :: \"entity \u21d2 bool\"\\n  PrimaryRepairPathways :: \"event \u21d2 bool\"\\n  Compromised :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  To :: \"event \u21d2 entity \u21d2 bool\"\\n  IncreasedRelianceOnAlternativeRepairMechanisms :: \"entity \u21d2 bool\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PARP1Inhibition :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Source :: \"event \u21d2 entity \u21d2 bool\"\\n  CumulativeDamage :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2 e3 e4. SyntheticLethality x \u2227 GeneticEvents y \u2227 LossOfBRCA2 z \u2227 Occurs e1 \u2227 Agent e1 x \u2227 CoOccurrence e2 \u2227 Agent e2 y \u2227 Result e3 \u2227 Agent e3 y \u2227 Patient e3 z \u2227 InabilityToRepair e3 \u2227 DNA z \u2227 Through e4 z \u2227 Agent e4 z\"\\n\\n(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3 e4 e5 e6. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cells w \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Force e3 \u2227 Agent e3 z \u2227 Patient e3 w \u2227 Rely e4 \u2227 Agent e4 w \u2227 On e5 w \u2227 On e6 w \u2227 Repair e5 \u2227 Agent e5 w \u2227 Patient e5 z\"\\n\\n(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3 e4 e5 e6. BRCA2Loss x \u2227 SyntheticLethality y \u2227 Cells z \u2227 Mechanism w \u2227 Cause e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Rely e2 \u2227 Agent e2 z \u2227 On e2 w \u2227 Repair e3 \u2227 Agent e3 z \u2227 Patient e3 e6 \u2227 CumulativeDNADamage e6 \u2227 PrimaryRepairPathways e4 \u2227 Compromised e4 \u2227 Lead e5 \u2227 Agent e5 e4 \u2227 To e5 IncreasedRelianceOnAlternativeRepairMechanisms\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 LossOfBRCA2 x \u2227 PARP1Inhibition y \u2227 SyntheticLethality z \u2227 Cells w\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z w e1 e2 e3 e4. Patients x \u2227 LossOfBRCA2 x \u2227 PARP1Inhibition y \u2227 SyntheticLethality z \u2227 Cells w \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Source e1 y \u2227 Cause e2 \u2227 Agent e2 z \u2227 Patient e2 w \u2227 Rely e3 \u2227 Agent e3 w \u2227 Mechanism e3 \u2227 Repair e4 \u2227 Agent e4 w \u2227 Patient e4 CumulativeDamage \u2227 To e4 DNA\"\\nproof -\\n  (* From the premise, we have known information about patients, loss of BRCA2, PARP1 inhibition, synthetic lethality, and cells. *)\\n  from asm have \"Patients x \u2227 LossOfBRCA2 x \u2227 PARP1Inhibition y \u2227 SyntheticLethality z \u2227 Cells w\" <ATP>\\n  \\n  (* Explanation 3 states that in the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage. *)\\n  (* This implies that with BRCA2 loss and synthetic lethality, cells rely on a singular mechanism. *)\\n  from explanation_3 have \"BRCA2Loss x \u2227 SyntheticLethality z \u27f6 (Rely e3 \u2227 Agent e3 w \u2227 Mechanism e3)\" <ATP>\\n  \\n  (* Since we have LossOfBRCA2 x and SyntheticLethality z from the premise, we can infer reliance on a singular mechanism. *)\\n  then have \"Rely e3 \u2227 Agent e3 w \u2227 Mechanism e3\" <ATP>\\n  \\n  (* Explanation 2 states that PARP inhibitors cause replication-associated double strand breaks, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining. *)\\n  (* This implies that PARP inhibitors lead to reliance on alternative repair mechanisms. *)\\n  from explanation_2 have \"PARPInhibitors y \u27f6 (Cause e2 \u2227 Agent e2 z \u2227 Patient e2 w \u2227 Rely e3 \u2227 Agent e3 w)\" <ATP>\\n  \\n  (* Since we have PARP1Inhibition y from the premise, we can infer the cause and reliance on repair mechanisms. *)\\n  then have \"Cause e2 \u2227 Agent e2 z \u2227 Patient e2 w \u2227 Rely e3 \u2227 Agent e3 w\" <ATP>\\n  \\n  (* Combining these inferences, we can conclude that patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA. *)\\n  then have \"Benefit e1 \u2227 Agent e1 x \u2227 Source e1 y \u2227 Cause e2 \u2227 Agent e2 z \u2227 Patient e2 w \u2227 Rely e3 \u2227 Agent e3 w \u2227 Mechanism e3 \u2227 Repair e4 \u2227 Agent e4 w \u2227 Patient e4 CumulativeDamage \u2227 To e4 DNA\" <ATP>\\n  \\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: loss of BRCA2 (from Explanatory Sentence 1)\\nC: cell death (from Explanatory Sentence 1)\\nD: inability to repair DNA damage through multiple pathways (from Explanatory Sentence 1)\\nE: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nF: prevention of single strand break repair (from Explanatory Sentence 2)\\nG: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nH: reliance on error-prone non-homologous end joining (from Explanatory Sentence 2)\\nI: singular mechanism to repair cumulative DNA damage (from Explanatory Sentence 3)\\nJ: primary repair pathways are compromised (from Explanatory Sentence 3)\\nK: increased reliance on alternative repair mechanisms (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(And(A, B), And(D, C))\\nImplies(A & B, C & D)\\n--------\\nImplies(F, E)\\nImplies(prevention of single strand break repair, PARP inhibitors cause replication-associated double strand breaks)\\n--------\\nImplies(E, And(G, H))\\nImplies(PARP inhibitors cause replication-associated double strand breaks, G & H)\\n--------\\nImplies(And(B, J), And(I, K))\\nImplies(B & J, I & K)\\n--------\\n\\nDerived Implications:\\nImplies(Not(G), Not(F))\\nImplies(Not(reliance on defective homologous recombination repair), Not(prevention of single strand break repair))\\n--------\\nImplies(Not(G), Not(E))\\nImplies(Not(reliance on defective homologous recombination repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(E, H)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(F, H)\\nImplies(prevention of single strand break repair, reliance on error-prone non-homologous end joining)\\n--------\\nImplies(Not(H), Not(F))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(prevention of single strand break repair))\\n--------\\nImplies(F, G)\\nImplies(prevention of single strand break repair, reliance on defective homologous recombination repair)\\n--------\\nImplies(E, G)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, reliance on defective homologous recombination repair)\\n--------\\nImplies(Not(H), Not(E))\\nImplies(Not(reliance on error-prone non-homologous end joining), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\n'}",
            "10 iteration: {'syntactic validity': False, 'error code': '', 'solving time': 6.7696568965911865, 'proof tactics': ['Type unification failed: Clash of types \"_ \\\\<Rightarrow> _\" and \"entity\"\\n\\nType error in application: incompatible operand type\\n\\nOperator:  Patient e3 :: entity \\\\<Rightarrow> bool\\nOperand:   CumulativeDNADamage :: entity \\\\<Rightarrow> bool\\n', 'No proof state', 'Bad context for command \"oops\"\\\\<^here> -- using reset state'], 'code': 'theory clinical_2_10\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  SyntheticLethality :: \"entity \u21d2 bool\"\\n  CoOccurrence :: \"entity \u21d2 bool\"\\n  GeneticEvents :: \"entity \u21d2 bool\"\\n  LossOfBRCA2 :: \"entity \u21d2 bool\"\\n  CellDeath :: \"entity \u21d2 bool\"\\n  Occurs :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Result :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Inability :: \"event \u21d2 bool\"\\n  Repair :: \"event \u21d2 bool\"\\n  DNADamage :: \"entity\"\\n  Through :: \"event \u21d2 entity \u21d2 bool\"\\n  MultiplePathways :: \"entity\"\\n  PARPInhibitors :: \"entity \u21d2 bool\"\\n  DoubleStrandBreaks :: \"entity \u21d2 bool\"\\n  SingleStrandBreakRepair :: \"entity \u21d2 bool\"\\n  Cells :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Prevent :: \"event \u21d2 bool\"\\n  Force :: \"event \u21d2 bool\"\\n  Rely :: \"event \u21d2 bool\"\\n  On :: \"event \u21d2 entity \u21d2 bool\"\\n  DefectiveHomologousRecombinationRepair :: \"entity\"\\n  ErrorProneNonHomologousEndJoining :: \"entity\"\\n  DNA :: \"entity\"\\n  BRCA2Loss :: \"entity \u21d2 bool\"\\n  CumulativeDNADamage :: \"entity \u21d2 bool\"\\n  SingularMechanism :: \"entity\"\\n  PrimaryRepairPathways :: \"entity \u21d2 bool\"\\n  Compromised :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  IncreasedReliance :: \"event \u21d2 bool\"\\n  AlternativeRepairMechanisms :: \"entity\"\\n  Patients :: \"entity \u21d2 bool\"\\n  PARP1Inhibition :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: Synthetic lethality occurs when the co-occurrence of multiple genetic events, such as the loss of BRCA2, results in cell death due to the inability to repair DNA damage through multiple pathways. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2 e3. SyntheticLethality x \u2227 CoOccurrence y \u2227 GeneticEvents y \u2227 LossOfBRCA2 y \u2227 CellDeath z \u2227 Occurs e1 \u2227 Agent e1 x \u2227 Result e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 Inability e3 \u2227 Repair e3 \u2227 Patient e3 DNADamage \u2227 Through e3 MultiplePathways\"\\n\\n(* Explanation 2: PARP inhibitors cause replication-associated double strand breaks by preventing single strand break repair, which forces cells to rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3 e4. PARPInhibitors x \u2227 DoubleStrandBreaks y \u2227 SingleStrandBreakRepair z \u2227 Cells w \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Prevent e2 \u2227 Agent e2 x \u2227 Patient e2 z \u2227 Force e3 \u2227 Agent e3 x \u2227 Patient e3 w \u2227 Rely e4 \u2227 Agent e4 w \u2227 On e4 DefectiveHomologousRecombinationRepair \u2227 On e4 ErrorProneNonHomologousEndJoining \u2227 Repair e4 \u2227 Patient e4 DNA\"\\n\\n(* Explanation 3: In the context of BRCA2 loss, synthetic lethality causes cells to rely on a singular mechanism to repair cumulative DNA damage, as the primary repair pathways are compromised, leading to an increased reliance on alternative repair mechanisms. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z w e1 e2 e3 e4. BRCA2Loss x \u2227 SyntheticLethality y \u2227 Cells z \u2227 CumulativeDNADamage w \u2227 Cause e1 \u2227 Agent e1 y \u2227 Patient e1 z \u2227 Rely e2 \u2227 Agent e2 z \u2227 On e2 SingularMechanism \u2227 Repair e2 \u2227 Patient e2 w \u2227 PrimaryRepairPathways v \u2227 Compromised v \u2227 Lead e3 \u2227 Agent e3 v \u2227 IncreasedReliance e4 \u2227 On e4 AlternativeRepairMechanisms\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patients x \u2227 LossOfBRCA2 x \u2227 PARP1Inhibition y \u2227 SyntheticLethality z\"\\n  (* Hypothesis: Patients with loss of BRCA2 may benefit from PARP1 inhibition due to synthetic lethality causing cells to rely on a singular mechanism to repair cumulative damage to DNA *)\\n  shows \"\u2203x y z e1 e2 e3. Patients x \u2227 LossOfBRCA2 x \u2227 PARP1Inhibition y \u2227 SyntheticLethality z \u2227 Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Cause e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 Rely e3 \u2227 Agent e3 x \u2227 On e3 SingularMechanism \u2227 Repair e3 \u2227 Patient e3 CumulativeDNADamage\"\\nproof -\\n  (* From the premise, we have known information about patients, loss of BRCA2, PARP1 inhibition, and synthetic lethality. *)\\n  from asm have \"Patients x \u2227 LossOfBRCA2 x \u2227 PARP1Inhibition y \u2227 SyntheticLethality z\" <ATP>\\n  (* Explanation 3 provides a logical relation Implies(And(B, J), And(I, K)), which implies that the loss of BRCA2 and compromised primary repair pathways lead to reliance on a singular mechanism and increased reliance on alternative repair mechanisms. *)\\n  (* Since we have LossOfBRCA2 x, we can infer that in the context of synthetic lethality, cells rely on a singular mechanism to repair cumulative DNA damage. *)\\n  then have \"Rely e3 \u2227 Agent e3 x \u2227 On e3 SingularMechanism \u2227 Repair e3 \u2227 Patient e3 CumulativeDNADamage\" <ATP>\\n  (* Explanation 2 suggests that PARP inhibitors cause replication-associated double strand breaks, which forces cells to rely on defective repair mechanisms. *)\\n  (* This supports the hypothesis that PARP1 inhibition may benefit patients with BRCA2 loss due to synthetic lethality. *)\\n  then have \"Benefit e1 \u2227 Agent e1 x \u2227 Patient e1 y\" <ATP>\\n  (* Combining these inferences, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: co-occurrence of multiple genetic events (from Explanatory Sentence 1)\\nB: loss of BRCA2 (from Explanatory Sentence 1)\\nC: cell death (from Explanatory Sentence 1)\\nD: inability to repair DNA damage through multiple pathways (from Explanatory Sentence 1)\\nE: PARP inhibitors cause replication-associated double strand breaks (from Explanatory Sentence 2)\\nF: prevention of single strand break repair (from Explanatory Sentence 2)\\nG: reliance on defective homologous recombination repair (from Explanatory Sentence 2)\\nH: reliance on error-prone non-homologous end joining (from Explanatory Sentence 2)\\nI: singular mechanism to repair cumulative DNA damage (from Explanatory Sentence 3)\\nJ: primary repair pathways are compromised (from Explanatory Sentence 3)\\nK: increased reliance on alternative repair mechanisms (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(And(A, B), And(D, C))\\nImplies(A & B, C & D)\\n--------\\nImplies(E, And(F, Or(G, H)))\\nImplies(PARP inhibitors cause replication-associated double strand breaks, F & (G | H))\\n--------\\nImplies(And(B, J), And(I, K))\\nImplies(B & J, I & K)\\n--------\\n\\nDerived Implications:\\nImplies(Not(F), Not(E))\\nImplies(Not(prevention of single strand break repair), Not(PARP inhibitors cause replication-associated double strand breaks))\\n--------\\nImplies(E, F)\\nImplies(PARP inhibitors cause replication-associated double strand breaks, prevention of single strand break repair)\\n--------\\n'}"
        ]
    }
}